<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00666237</url>
  </required_header>
  <id_info>
    <org_study_id>20071037</org_study_id>
    <secondary_id>NEI Grant No. EY014801</secondary_id>
    <nct_id>NCT00666237</nct_id>
  </id_info>
  <brief_title>Primary Tube Versus Trabeculectomy Study</brief_title>
  <official_title>Primary Tube Versus Trabeculectomy Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott Medical Optics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Research to Prevent Blindness</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the Primary Tube Versus Trabeculectomy (PTVT) Study is to compare the&#xD;
      long-term safety and efficacy of nonvalved tube shunt surgery to trabeculectomy with&#xD;
      mitomycin C in eyes that have not had previous ocular surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2008</start_date>
  <completion_date type="Actual">April 1, 2021</completion_date>
  <primary_completion_date type="Actual">April 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Intraocular pressure will be reported in mmHg and measured using Goldmann applanation tonometry or a Tono-Pen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complication rates</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Percentage of participants with reported complications from intervention will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity using a Snellen Chart</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Visual acuity will be measured using different sized letters on a Snellen chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity using an EDTRS chart</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Visual acuity will be measured using different sized letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual field</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Visual fields will be measured using standard automated perimetry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reoperation for glaucoma</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The number of participants requiring reoperation for glaucoma will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supplemental medical therapy</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The number of participants requiring supplemental medical therapy for glaucoma will be reported</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">242</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Tube shunt surgery group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive a tube shunt surgery (Baerveldt Glaucoma implant).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trabeculectomy with Mitomycin C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive a Trabeculectomy surgery with Mitomycin C</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tube shunt surgery</intervention_name>
    <description>The procedure involves implantation of a Baerveldt consisting of a tube that is connected to an end plate. The tube is inserted into the anterior chamber and shunts aqueous humor to the end plate located in the equatorial region of the eye. The aqueous humor is then absorbed by the tissues around the eye.</description>
    <arm_group_label>Tube shunt surgery group</arm_group_label>
    <other_name>Baerveldt glaucoma implant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Trabeculectomy</intervention_name>
    <description>The procedure involves removal of a small portion of trabecular meshwork and adjacent tissue under a partial thickness scleral flap. Aqueous humor drains into the subconjunctival space producing a filtering bleb. The aqueous humor then diffuse out of the bleb.</description>
    <arm_group_label>Trabeculectomy with Mitomycin C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin C</intervention_name>
    <description>A fluid retaining sponge soaked in 0.4 mg/ml Mitomycin C will be applied in the region of Trabeculectomy site for about 2 minutes</description>
    <arm_group_label>Trabeculectomy with Mitomycin C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-85 years&#xD;
&#xD;
          -  Glaucoma that is inadequately controlled on tolerated medical therapy with IOP greater&#xD;
             than or equal to 18 mm Hg and less than or equal to 40 mm Hg&#xD;
&#xD;
          -  No previous incisional ocular surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwilling or unable to give consent, unwilling to accept randomization, or unable to&#xD;
             return for scheduled protocol visits&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  No light perception vision&#xD;
&#xD;
          -  Active iris neovascularization or active proliferative retinopathy&#xD;
&#xD;
          -  Iridocorneal endothelial syndrome&#xD;
&#xD;
          -  Epithelial or fibrous ingrowth&#xD;
&#xD;
          -  Chronic or recurrent uveitis&#xD;
&#xD;
          -  Steroid-induced glaucoma&#xD;
&#xD;
          -  Severe posterior blepharitis&#xD;
&#xD;
          -  Unwilling to discontinue contact lens use after surgery&#xD;
&#xD;
          -  Previous cyclodestructive procedure&#xD;
&#xD;
          -  Conjunctival scarring from prior ocular trauma or cicatrizing disease precluding a&#xD;
             superior trabeculectomy&#xD;
&#xD;
          -  Functionally significant cataract&#xD;
&#xD;
          -  Need for glaucoma surgery combined with other ocular procedures or anticipated need&#xD;
             for additional ocular surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven J Gedde, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Bascom Palmer Eye Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dale K Heuer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard K Parrish, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Bascom Palmer Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Eye and Ear Infirmary</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glaucoma Associates of Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas, Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toronto</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Thomas' Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary's Sidcup Hospital</name>
      <address>
        <city>Sidcup</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gedde SJ, Chen PP, Heuer DK, Singh K, Wright MM, Feuer WJ, Schiffman JC, Shi W; Primary Tube Versus Trabeculectomy Study Group. The Primary Tube Versus Trabeculectomy Study: Methodology of a Multicenter Randomized Clinical Trial Comparing Tube Shunt Surgery and Trabeculectomy with Mitomycin C. Ophthalmology. 2018 May;125(5):774-781. doi: 10.1016/j.ophtha.2017.10.037. Epub 2017 Dec 18.</citation>
    <PMID>29248173</PMID>
  </reference>
  <results_reference>
    <citation>Gedde SJ, Feuer WJ, Lim KS, Barton K, Goyal S, Ahmed IIK, Brandt JD; Primary Tube Versus Trabeculectomy Study Group. Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 3 Years of Follow-up. Ophthalmology. 2020 Mar;127(3):333-345. doi: 10.1016/j.ophtha.2019.10.002. Epub 2019 Oct 9.</citation>
    <PMID>31727428</PMID>
  </results_reference>
  <results_reference>
    <citation>Gedde SJ, Feuer WJ, Shi W, Lim KS, Barton K, Goyal S, Ahmed IIK, Brandt J; Primary Tube Versus Trabeculectomy Study Group. Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 1 Year of Follow-up. Ophthalmology. 2018 May;125(5):650-663. doi: 10.1016/j.ophtha.2018.02.003. Epub 2018 Feb 21.</citation>
    <PMID>29477688</PMID>
  </results_reference>
  <results_reference>
    <citation>Gedde SJ, Feuer WJ, Chen PP, Heuer DK, Singh K, Wright MM; Tube Versus Trabeculectomy and Primary Tube Versus Trabeculectomy Study Groups. Comparing Treatment Outcomes from the Tube Versus Trabeculectomy and Primary Tube Versus Trabeculectomy Studies. Ophthalmology. 2021 Feb;128(2):324-326. doi: 10.1016/j.ophtha.2020.06.059. Epub 2020 Jul 2.</citation>
    <PMID>32622848</PMID>
  </results_reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 23, 2008</study_first_submitted>
  <study_first_submitted_qc>April 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2008</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Steven J. Gedde</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Tube shunt surgery</keyword>
  <keyword>Trabeculectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

